Feature

Solving the Problem of Insolubility: Part II

KinetiSol’s solvent-free mixing process turns “brick dust” drugs into stable amorphous dispersions

  • By

  • February 24, 2026

  • 6 min

Share

In a discussion led by CEO Elizabeth Hickman and CSO Dave Miller of Austin Px, the focus is on the innovative KinetiSol technology, which addresses solubility challenges in drug formulation. Initially aimed at enhancing manufacturing efficiency, KinetiSol targets 'brick dust molecules,' which are largely insoluble and unmet by traditional methods. This technology leverages mechanical energy and excipient-based solvents to create improved drug delivery systems, enhancing solubility and speeding up the process, marking a significant advancement in pharmaceutical manufacturing.

Original Source(s)

Solving the Problem of Insolubility: Part II

KinetiSol’s solvent-free mixing process turns “brick dust” drugs into stable amorphous dispersions

  • February 24, 2026

  • 6 min

Related Content

Sticky Situation; Sticky Solution 

Image of the Month: engineered algae aggregating microplastics

  • February 20, 2026

  • 1 min
UK: More than a Million Over 40s Living with Glaucoma

New modeling data estimate higher glaucoma prevalence in the UK, with cases expected to increase over the coming decades

  • February 20, 2026

  • 3 min
How Lead Exposure Changed Over a Century 

Hair-based mass spectrometry links declining lead exposure to environmental regulation 

  • February 17, 2026

  • 2 min